DXR
Daxor Corporation
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$10.27
−2.66%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 868.5K | 503.4K | 2.1M | 34.6M | (353.4K) |
| Cost of Revenue | 394.5K | 314.7K | — | 177.1K | 1.1M |
| Gross Profit | 474.0K | 188.7K | 2.1M | 34.4M | (1.4M) |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | (14.65) |
| SG&A Expense | 1.5M | — | 294.2K | 307.4K | 1.1M |
| General & Admin Expense | 283.2K | — | 294.2K | 307.4K | 1.1M |
| Selling & Marketing Expense | 1.2M | — | — | — | — |
| Other Expenses | (6.3M) | (9.0M) | 1.3M | 631.7K | 14.65 |
| Total Operating Expenses | (4.9M) | (9.0M) | 1.6M | 939.1K | 1.1M |
| Cost and Expenses | (7.3M) | (8.7M) | 1.6M | 34.3M | (5.6M) |
| Operating Income (EBIT) | 8.2M | 9.2M | 621.4K | 329.7K | 5.3M |
| Non-Operating | |||||
| Interest Income | 41.1K | 26.7K | — | — | — |
| Interest Expense | 16.0K | 16.0K | 85.1K | 49.1K | 72.5K |
| Net Interest Income | 25.2K | 10.7K | (85.1K) | (49.1K) | (72.5K) |
| Other Non-Op Income/Expense | (141.7K) | (16.0K) | (85.1K) | (49.1K) | (72.5K) |
| Non-Operating Income (excl Interest) | 20.9K | — | — | — | — |
| EBT (Pre-Tax Income) | 8.0M | 9.2M | 536.3K | 280.6K | 5.2M |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | 8.0M | 9.2M | 536.3K | 280.6K | 5.2M |
| Earnings from Cont. Ops | 8.0M | 9.2M | 536.3K | 280.6K | 5.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 8.0M | 9.2M | 536.3K | 280.6K | 5.2M |
| Per Share | |||||
| Basic EPS | $1.60 | $1.84 | $0.11 | $0.06 | $0.60 |
| Diluted EPS | $1.60 | $1.84 | $0.11 | $0.06 | $0.60 |
| Revenue Per Share | $0.17 | $0.10 | $0.44 | $7.47 | ($0.04) |
| Shares | |||||
| Basic Shares Outstanding | 5.0M | 5.0M | 4.8M | 4.6M | 8.6M |
| Diluted Shares Outstanding | 5.0M | 5.0M | 4.8M | 4.6M | 8.6M |
| Profitability Metrics | |||||
| EBITDA | 9.6M | 9.2M | 2.1M | 329.7K | 6.1M |
| D&A | 1.4M | — | 1.4M | 506.8K | 859.7K |
| EBIT | 8.2M | 9.2M | 621.4K | 329.7K | 5.3M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026